Evaluation of five selective media for the detection of Pseudomonas aeruginosa using a strain panel from clinical, environmental and industrial sources

Journal of Microbiological Methods

Volumn 99, Issue 1, 2014, Pages 8-14

  Weiser, Rebecca ^a   Donoghue, Denise ^b   Weightman, Andrew ^a   Mahenthiralingam, Eshwar ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNILEVER RESEARCH   (United Kingdom)

Author keywords

Culture dependent detection; Pseudomonas aeruginosa; Selective media

Indexed keywords

CULTURE-DEPENDENT DETECTION; PSEUDOMONAS AERUGINOSA; SELECTIVE MEDIA;

BACTERIOLOGICAL TECHNIQUES; CULTURE MEDIA; PSEUDOMONAS AERUGINOSA; SENSITIVITY AND SPECIFICITY;

EID: 84893731731     PISSN: 01677012     EISSN: 18728359     Source Type: Journal    
DOI: 10.1016/j.mimet.2014.01.010     Document Type: Article

References (30)

1. Bador J., Amoureux L., Duez J.-M., Drabowicz A., Siebor E., Llanes C., Neuwirth C. First description of a RND-type multidrug efflux pump in Achromobacter xylosoxidans: AxyABM. Antimicrob. Agents Chemother. 2011, 55:4912-4914.
2. Deschaght P., Van daele S., De Baets F., Vaneechoutte M. PCR and the detection of Pseudomonas aeruginosa in respiratory samples of cystic fibrosis patients. A literature review. J. Cyst. Fibros. 2011, 10:293-297.
3. De Vos D., Lim A., Pirnay J.P., Struelens M., Vandenvelde C., Duinslaeger L., Vanderkelen A., et al. Direct detection and identification of Pseudomonas aeruginosa in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane lipoprotein genes, oprI and oprL. J. Clin. Microbiol. 1997, 35:1295-1299.
4. FDA Bacteriological analytical manual 1998, (Revision A, Chapter 23 [Online]. Available at: http://www.fda.gov/food/scienceresearch/laboratorymethods/bacteriologicalanalyticalmanualbam/ucm073598.htm [Accessed: 28/06/12]). 8th edition.
5. Gomez M., Prince A. Opportunistic infections in lung disease: Pseudomonas infection in cystic fibrosis. Curr. Opin. Pharmacol. 2007, 7:244-251.
6. Hauser A.R., Jain M., Bar-Meir M., McColley S.A. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Microbiol. Rev. 2011, 24:29-70.
7. Hogardt M., Ulrich J., Riehn-Kopp H., Tümmler B. EuroCareCF quality assessment of diagnostic microbiology of cystic fibrosis isolates. J. Clin. Microbiol. 2009, 47:3435-3438.
8. Jimenez L. Microbial diversity in pharmaceutical product recalls and environments. PDA J. Pharm. Sci. Technol. 2007, 61:383-399.
9. Jimenez L., Ignar R., Smalls S., Grech P., Hamilton J., Bosko Y., English D. Molecular detection of bacterial indicators in cosmetic/pharmaceuticals and raw materials. J. Ind. Microbiol. Biotechnol. 1999, 22:93-95.
10. Jimenez L., Smalls S., Ignar R. Use of PCR analysis for detecting low levels of bacteria and mold contamination in pharmaceutical samples. J. Microbiol. Methods 2000, 41:259-265.
11. Kerr K.G., Snelling A.M. Pseudomonas aeruginosa: a formidable and ever-present adversary. J. Hosp. Infect. 2009, 72:338-344.
12. King E.O., Ward M.K., Raney D.E. Two simple media for the demonstration of pyocyanin and fluorescein. J. Lab. Clin. Med. 1954, 44:301-307.
13. Kodaka H., Iwata M., Yumoto S., Kashitani F. Evaluation of a new agar medium containing cetrimide, kanamycin and nalidixic acid for isolation and enhancement of pigment production of Pseudomonas aeruginosa in clinical samples. J. Basic Microbiol. 2003, 43:407-413.
14. Laine L., Perry J.D., Lee J., Oliver M., James A.L., De La Foata C., Halimi D., et al. A novel chromogenic medium for isolation of Pseudomonas aeruginosa from the sputa of cystic fibrosis patients. J. Cyst. Fibros. 2009, 8:143-149.
15. Lalkhen A.G., McCluskey A. Clinical tests: sensitivity and specificity. Contin. Educ. Anaesth., Crit. Care Pain 2008, 8:221-223.
16. Leisinger T., Margraff R. Secondary metabolites of the fluorescent pseudomonads. Microbiol. Rev. 1979, 43:422-442.
17. Li X.-Z., Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs 2009, 69:1555-1623.
18. Lilly H.A., Lowbury E.J. Cetrimide-nalidixic acid agar as a selective medium for Pseudomonas aeruginosa. J. Med. Microbiol. 1972, 5:151-153.
19. Morrison A.J., Wenzel R.P. Epidemiology of infections due to Pseudomonas aeruginosa. Rev. Infect. Dis. 1984, 6:S627-S642.
20. Perry J.D., Freydière A.M. The application of chromogenic media in clinical microbiology. J. Appl. Microbiol. 2007, 103:2046-2055.
21. Reyes E.A., Bale M.J., Cannon W.H., Matsen J.M. Identification of Pseudomonas aeruginosa by pyocyanin production on Tech agar. J. Clin. Microbiol. 1981, 13:456-458.
22. Rose H., Baldwin A., Dowson C.G., Mahenthiralingam E. Biocide susceptibility of the Burkholderia cepacia complex. J. Antimicrob. Chemother. 2009, 63:502-510.
23. Smirnov V.V., Kiprianova E.A. Bacteria of the Pseudomonas genus 1990, 100-111. Naukova Dumka, Kiev, USSR.
24. Spilker T., Coenye T., Vandamme P., LiPuma J.J. PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients. J. Clin. Microbiol. 2004, 42:2074-2079.
25. Stover C.K., Pham X.Q., Erwin A.L., Mizoguchi S.D., Warrener P., Hickey M.J., Brinkman F.S.L., et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000, 406:959-964.
26. Sutton S., Jimenez L. A review of reported recalls involving microbiological control 2004-2011 with emphasis on FDA considerations of 'objectionable organisms'. Am. Pharm. Rev. 2012, 15:42-57.
27. Szita G., Tabajdi V., Fábián A., Biró G., Reichart O., Körmöczy P.S. A novel, selective synthetic acetamide containing culture medium for isolating Pseudomonas aeruginosa from milk. Int. J. Food Microbiol. 1998, 43:123-127.
28. Szita G., Gyenes M., Soós L., Rétfalvi T., Békési L., Csikó G., Bernáth S. Detection of Pseudomonas aeruginosa in water samples using a novel synthetic medium and impedimetric technology. Lett. Appl. Microbiol. 2007, 45:42-46.
29. Thomas S.R., Ray A., Hodson M.E., Pitt T.L. Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax 2000, 55:795-797.
30. Winstanley C., Langille M.G.I., Fothergill J.L., Kukavica-Ibrulj I., Paradis-Bleau C., Sanschagrin F., Thomson N.R., et al. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res. 2009, 19:12-23.